Translate AMICOR contents if you like

Wednesday, December 07, 2016

solanezumab faillure

Amyloid Drug Fails Major Trial 
The anti-amyloid agent solanezumab failed to meet its primary endpoint in the highly anticipated EXPEDITION3 trial, drugmaker Eli Lilly announced.

Patients with mild dementia who were given the monoclonal antibody didn't have a significant slowdown in cognitive decline as measured by the ADAS-Cog14 compared with those given placebo (P=0.095), the company said. 

No comments: